I don't think there are any convertibles at deep discounts left, and it looks like TAUG stock investments are doing well, so I think they have cash available.
VTGN is up and trading in the low 2's with a Phase 3 readout on the first SAD drug that the FDA has fast tracked and given needed status to. VTGN now has massive institutional ownership and analysts are calling for $9.00 just on that one drug, which isn't there biggest. VTGN went from 0 institutions owning it to some of the biggest, I believe it is over 55% institutionally owned. Including by Franklin Templeton. Funny how Seth's rolodex includes the Head of Global at Franklin.
AXIM.. That stock is up double and could easily double again. The drug works and had a snafu on paperwork submitted to FDA. Keep an eye on that one.
GOEV (W) Looks like things are heating up there finally. They have received nearly $500 million bucks from Arkansas and appear to have over $1 billion in orders for its electric pickup.
Aegea will get interesting because of the latest news, and we are in flu season and new variants.
Serendipity Brands is about to launch a massive advertising campaign with Selena Gomez and I was told that there is discussions with Nesltes about doing 3 drink flavors. They are also launching other products.
While the Serendipity restaurants are not part of the Serendipity Brands they will promote ice cream for sure. NY location, where Presidents and famous stars have gone is remodeled. Miami has opened, and 8 other locations are being built, including inside Disney. The Walburg's have also signed an agreement to put 6 locations up.
GoPuff is a huge partner in Serendipity Brands. They also deliver alcohol in the States where it is allowed. Taug's products could fit in nicely there. I don't think many people at GoPuff are over 35 years old so maybe these products will interest them.
But like I have said repeatedly, the nausea drug trial for chemo patients is the biggest driver for me. I doubt much will happen till the patent is issued, besides the ongoing safety cohort.
If a company like BNOEF can retain 40% of its ownership in its drug through a partnership with MERC I can't see why Tauriga cannot enter into an arrangement like that with a Pharma player. The nausea market is a $7 billion plus annual market and the trial from soup to nuts will be under $80,000,000 That is a bargain as blockbuster drugs average over $1.5 billion dollars on average.
